India-UK CETA left investment, pharma IP and carbon tax unresolved
The India-UK Comprehensive Economic and Trade Agreement (CETA) took effect on July 15, 2026 with tariff cuts on 99% of Indian exports, but three high-friction issues — investment protection, pharmaceutical patent standards and the UK's carbon border tax — were kept out of the deal.
What happened
CETA came into force on July 15, 2026, cutting tariffs on 99% of Indian exports to the UK and loosening some mobility rules for professionals. Commerce Minister Piyush Goyal has said the deal covers only issues where both sides could agree; three unresolved gaps remain. First, CETA has no dedicated investment chapter, unlike India's earlier agreements with the European Free Trade Association (EFTA) and New Zealand. Second, UK pharmaceutical firms will not get wider access to the Indian market because India kept Section 3(d) of The Patents Act, 1970, which curbs 'evergreening' of patents on minor drug modifications. Third, the UK's Carbon Border Adjustment Mechanism (CBAM), which starts on January 1, 2027, sits outside CETA entirely and will still apply to Indian steel, aluminium and cement.
Context
India cancelled almost all its Bilateral Investment Treaties (BITs) in 2017, moving away from a regime that let a foreign investor go straight to international arbitration if a dispute arose with the Indian government. Under the current position, investors must first exhaust the Indian legal process for a set period before arbitration is available. That change of stance has stalled BIT talks with several partners, including the UK. On pharmaceuticals, the UK exports around £26 billion of medicines globally but only £127 million, or 0.5%, to India, precisely because Indian generics manufactured under Section 3(d) already meet most demand — and the UK's own National Health Service is a large buyer of those Indian generics. On CBAM, the UK's trade commissioner for South Asia has said 'we made it clear from day one that CBAM was never part of the FTA'.
Why it matters
CETA reads as a tariff-and-market-access agreement, not a full economic integration treaty. That distinction matters for exam-relevant frameworks: economic integration usually moves through free trade area, then customs union, then common market, then economic union, layering in factor mobility, investment rules and regulatory harmonisation as it deepens. CETA sits at the first rung — border-tariff liberalisation — and deliberately postpones the harder second-rung questions (investor-state dispute settlement, IP standards, cross-border carbon adjustments) that shape actual capital and technology flows. It also shows the limits of trade deals as a shield against unilateral climate policy: an FTA can cut a UK import duty on Indian steel while a separate CBAM charge is layered on for the same shipment.
Impact for India
- Indian steel, aluminium and cement exporters get the tariff benefit today but face the UK's CBAM charge from January 1, 2027, likely offsetting part of the benefit for carbon-intensive shipments.
- Indian generic pharmaceutical manufacturers retain their competitive position in the UK because India held Section 3(d) intact, keeping the door open to generics after the original patent expires.
- UK pharmaceutical exporters continue to face a narrow Indian market — the UK's own numbers show only 0.5% of its £26 billion medicine exports go to India.
- UK investors into India have no CETA-based investment protection or investor-state dispute mechanism; disputes route through Indian courts before any international arbitration.
- Indian exporters of professional services get some easier mobility, but the deal stops well short of the deeper commitments seen in the EFTA and New Zealand agreements.
Key data
Concepts
Theory lens
Stages of economic integration (Balassa) — free trade area, customs union, common market, economic union
Stakeholders
Practice Question — from the story
With reference to the India-U.K. Comprehensive Economic and Trade Agreement (CETA), consider the following statements:
- CETA came into force on July 15, 2026 and includes a dedicated investment chapter modelled on India's earlier agreements with EFTA and New Zealand.
- The U.K.'s Carbon Border Adjustment Mechanism (CBAM), due to come into force on January 1, 2027, was kept outside CETA and will still apply to Indian exports of steel, aluminium and cement.
Which of the statements given above is/are correct?
Reveal answer & explanation
Answer: 2 only
- Statement 1: Incorrect. CETA did come into force on July 15, 2026, but the source is explicit that CETA has no dedicated investment chapter, unlike India's EFTA and New Zealand agreements which do include investment commitments.
- Statement 2: Correct. The U.K. trade commissioner said CBAM 'was never part of the FTA'; CBAM starts on January 1, 2027 and will still charge Indian steel, aluminium and cement exporters even after CETA tariffs fall.
Therefore, the correct answer is 2 only.
Concept check — test your understanding
In pharmaceutical patent policy, 'evergreening' — the practice that India's Section 3(d) is designed to curb — refers to which of the following?
Reveal answer & explanation
Answer: D
- Evergreening is the strategy of stacking incremental patents (new salt, new dosage form, new combination) on top of an expiring one to keep generics out; Section 3(d) requires an enhanced-therapeutic-efficacy test for such follow-on patents in India.
- Option A describes patent-based transfer pricing, a tax rather than patent-term strategy.
- Option B describes compulsory licensing, a mechanism that overrides an active patent, not one that extends it.
- Option C describes process patents — India's older process-only regime — which is a distinct patent-scope question, not a term-extension strategy.